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A B S T R A C T   
The cold neutron beam at the PF1b line at the Institut Laue-Langevin (ILL), without fast neutrons and a low contribution of gamma rays, is a very suitable facility to 
measure cell damage following low-energy neutron irradiation. The biological damage associated with the thermal and the boron doses can be obtained in order to 
evaluate the relative biological effectiveness (RBE) for Boron Neutron Capture Therapy. 
Three different experiments were carried out on the A375 melanoma cell line: the first one in a hospital LINAC, to obtain the reference radiation data, and the other 
two at the ILL, in which the damage to cells with and without boron compounds added was measured.   
1. Introduction 
Boron neutron capture therapy (BNCT) is a unique form of external 
radiotherapy that is selective at the cellular level and has already pro-
duced promising results in various clinical trials worldwide. One of the 
main problems for the development of BNCT is that the dosimetry and 
treatment planning has not reached the accuracy of other more con-
ventional radiotherapies (Wennervirta et al., 2019). Hence, a better 
estimation of the biological damage produced by the dose delivered in 
BNCT is essential. 
There are four main dose components during BNCT neutron irradi-
ation (Goorley et al., 2002): Dt, thermal neutron dose mostly due to the 
reaction 14N(n,p)14C; Df , fast neutron dose arising mainly from neutron 
collisions with hydrogen; Dγ, from gamma rays either coming together 
with the neutron beam or emitted after a neutron capture; and DB, the 
boron dose, arising from neutron capture by boron compounds accu-
mulated in the cells. The total biological dose, Dw, is normally written in 
a form that contains weighting factors (or relative biological effective-
ness, RBE) for each component of the dose and is compared to a refer-
ence photon dose, D0. These weighting factors are defined as wi  D0= Di 
for a particular endpoint. The biological dose (also called weighted dose 
or effective dose) is then expressed as 
DW  wf Df  wtDt  wγDγ  wBDB  D0: (1) 
No cell repair or synergy effects are taken into account in this bio-
logical dose estimation. More sophisticated radiobiological formalisms 
take into account the linear-quadratic response of cells to radiation 
(Gonzalez and Cruz, 2012; Pedrosa-Rivera et al., 2020a). However, all 
models require good experimental data for a correct estimation of the 
biological dose. Given that the biological effect depends on the types of 
cells under study and on the end-point, it is important to obtain data for 
a range of different conditions. 
Some of the weighting factors currently used were obtained from 
glioblastoma rat models irradiated at the Brookhaven Medical Research 
Reactor using a neutron beam where more than 30% of the dose was 
from gamma rays and more than 45% from fast neutrons (Coderre et al., 
1993). The data extracted from those experiments have been used in 
BNCT for years for different tumor types. Dedicated radiobiological data 
for other tissues using “clean” neutron beams may help to better adapt 
the dose for each treatment. Moreover, the difficulty of isolating the 
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effect of thermal neutrons led to the use of equal neutron weighting 
factors for thermal and epithermal dose components; this assumption 
has not yet been justified on the basis of experimental data (Hopewell 
et al., 2011). For this reason, irradiation studies in well-characterized 
low energy neutron beams are essential in establishing each weighting 
factor. 
For thermal and slower neutrons almost all capture cross-sections are 
inversely proportional to the neutron velocity (Mughabghab, 1997). 
Moreover, the energies of the incident neutrons are negligible compared 
to the Q value of the capture reaction. Consequently, the physical dose 
and biological effect are proportional to the number of captures, irre-
spective of the exact thermal or subthermal neutron spectrum. Thus, 
“clean” cold neutron beams are perfect surrogates for the study of 
thermal neutron radiobiology. 
The beam line PF1b at the ILL high-flux reactor provides a high flux 
cold neutron beam where biological experiments can be performed 
(Abele et al., 2006). The absence of fast neutrons and contaminating 
gamma rays, and an optimized experimental arrangement, means that 
experiments to evaluate the weighting factors wt and wB can be carried 
out (Pedrosa-Rivera et al., 2020b). 
Three different experiments were carried out in order to obtain the 
wt and wB for the A375 melanoma cell line. The first was performed with 
a photon beam from a hospital linear accelerator (LINAC) and served as 
the reference dose. The other two, which were aimed at identifying the 
effect of low energy neutrons without and with the addition of BPA, 
were performed on PF1b at ILL. The end-point of clonogenic ability was 
studied after the irradiations. Different reference dose data were used to 
check the influence on the variability of the different RBE. 
2. Materials and methods 
2.1. Cell culture 
A375 cells were kindly provided by Dr. Lucie Sancey (Institute for 
Advanced Biosciences, Grenoble) and cultivated in RPMI medium 
(HyClone, Logan, USA) completed with 10% fetal bovine serum (FBS; 
Gibco, California, USA), 1 μM L-glutamine (Gibco) and 100 IU/ml 
penicillin and 100 IU/ml streptomycin (Sigma-Aldrich, St. Louis, USA) 
at 37 C in a humidified CO 2, 95% air incubator. 
2.2. Irradiations at the medical LINAC 
The photon irradiations were carried out at an Elekta Versa HD™ 6 
MV medical LINAC at the university hospital “Virgen de las Nieves” in 
Granada. Cells were seeded in common T25 cell culture flasks (Sigma- 
Aldrich, St Louis, MO, USA). The accelerator has a source surface dis-
tance (DFS) of 100 cm. To guarantee electronic equilibrium, the flasks, 
filled with culture media, were placed inside a PMMA (poly-
methylmethacrylate) cask full of distilled water and situated above 14 
cm of solid water, similar to previous gamma irradiation experiments 
(Mackonis et al., 2007; Butterworth et al., 2010) (see Fig. 1). A 
computed tomography scan of the set-up was processed through the 
treatment-planning program (Pinnacle, Philips) for dose calculation and 
in order to design the field size where the cells are homogeneously 
irradiated. Cells were irradiated with 0,5, 2, 4 and 6 Gy at a dose rate of 
1 Gy/min. 
2.3. Irradiations at ILL 
The PF1b line is situated 80 m away from a liquid deuterium cold 
source in ILL’s high flux reactor. A ballistic supermirror bent-guide 
conducts the cold neutron beam to the experimental area. Fast neu-
trons and gamma rays from the reactor are not transported by such a 
guide. A 2.5 m long collimation system made of a series of lead-backed 
boron carbide and lithium fluoride collimators was used to constrain the 
beam to a pencil-like shape of 2 cm diameter. After the collimation, the 
thermal equivalent capture flux was determined by gold foil activation 
as 1.05⋅109cm-2s-1 in September 2018 and 2.85⋅109 cm-2s-1 in June 
2019, depending on the reactor power and the upstream collimator 
sizes. 
Cells were attached inside quartz cuvettes of 2 mm width (in beam 
direction) filled with culture media. Two cuvettes, arranged one behind 
the other, were irradiated at the same time. The neutron scattering in 
water results in a reduction of the capture flux, and thus the neutron 
dose, by about a factor two from the first to the second sample. Thus, per 
simultaneous irradiation of such a sample stack, two data points 
differing by a factor two in neutron dose were obtained. The sample 
irradiation position was surrounded by the first layer of 6LiF shielding to 
avoid secondary gamma-ray emission from scattered neutrons. The 
beam, set-up and related simulations have been described in previous 
work (Pedrosa-Rivera et al., 2020b). 
Fig. 1. Experimental arrangements used for the sample irradiation at the two different facilities. For the medical LINAC, cells are attached inside T25 flasks that are 
submerged in distilled water. For the irradiation at ILL, cells are attached inside 2 mm quartz cuvettes. 
M. Pedrosa-Rivera et al.                                                                                                                                                                                                                       
Applied Radiation and Isotopes 163 (2020) 109205
3
Irradiation times for samples without boron compound were from 
15 min to 75 min while the boron-containing samples were irradiated 
between 1 and 3 min. 
An L2 (level 2 safety) biological lab installed near PF1b enabled 
efficient cell management and high throughput of experiments. 
2.4. Boron compound measurements 
BPA (Boronophenylalanine) 95% enriched in 10B was added to the 
culture media 5 h prior to irradiation in a 80 ppm concentration. The 
medium was changed to a boron-free medium 5 min before the irradi-
ations to avoid any involvement of the captures in the media on the cell 
effect. 
Boron uptake measurements were carried out by neutron autoradi-
ography (Postuma et al., 2016). This was performed in the thermal 
column of the TRIGA MARK II nuclear research reactor at LENA labo-
ratories of the University of Pavia. Cells were dried on the top of a mylar 
foil that was then positioned on a CR39 track detector. Upon neutron 
capture by boron in the cell sample, the recoiling alphas entered the 
CR39 and induced structural damage along their tracks. These latent 
tracks were then revealed by etching in a PEW40 solution (KOH 
C2H5OH  H2O). Tracks were then recorded with a Leica MZ16A mi-
croscope in transmission light through a CCD camera. Images were 
analyzed using track counting software which returns the track density. 
This value can then be related to the boron concentration in the cell 
sample by using the appropriate calibration curve. 
2.5. Survival assay 
After irradiation in the medical LINAC and at ILL, cells were de-
tached, counted and prepared for clonogenic assay. Colonies were 
counted after 7 days, and the survival was expressed according to the 
plating efficiency calculated. 
2.6. Determination of RBE 
The survival curves obtained after irradiations can be described by 







e  αiDi   βiD2i ; (2)  
where the index i refers to the different dose components: gamma, 
thermal and boron (there is no epithermal dose component in any of the 
present irradiations). In the irradiation at the medical LINAC, the effect 
is only due to gamma rays therefore survival can be described with αγ 
and βγ parameters. At ILL, for cells without boron compound, the dose is 
mostly delivered by cold neutrons and by secondary capture gamma rays 
from the sample holder (see Table 1), so parameters αγ, βγ, αn, βn will be 
needed to trace the curve. The effect due only to the neutrons can be 
extracted using equation (2). Finally, for BPA-containing samples, the 
survival effect will be described by the product of Sγ ; Sn and SB, where SB 
corresponds to neutrons captured in boron, which makes it compound 
dependent. SB is then derived by comparison with the survival curves of 
boron free cell assays . 
Once αn, βn (and αB, βB) are estimated, the RBE can be calculated by 
the ratio between a reference irradiation dose with photons and the dose 
corresponding to just neutrons (or to captures in boron respectively), for 
a specific survival. 
3. Results 
3.1. Dosimetry 
Doses at the PF1b neutron beam at ILL were determined by Monte 
Carlo simulations with MCNPX program, as reported in detail in 
(Pedrosa-Rivera et al., 2020b). Table 1 shows the dose rates of each dose 
component in the described configuration. 
3.2. A375 survival 
Cell survival after the three different irradiations is shown in Fig. 2 
plotted against the total absorbed dose. Boron uptake measurements 
indicate 334 ppm of 10B inside the cells. The total absorbed dose is 
estimated using the kerma factor per ppm assuming that the boron is 
uniformly distributed inside the cells. Obviously, the effect of boron 
capture is significantly higher than that of the other irradiation types. 
The fitting parameters of the curves, αi and βi, are shown in Table 2 
3.3. Weighting factors (RBE factors) from different reference doses 
Photons dose is taken as the reference radiation (D0). However, a 
disparity is found in the data regarding cell survival under different 
photon irradiations. By analyzing different results of A375 cell irradia-
tion from nine different experiments (with dose rates of 0.2–6 Gy/min) 
three from 137Cs irradiators (Munshi et al., 2005; Munshi et al., 2006; 
Gomez-Millan et al., 2012), three from X-rays tubes of around 200 kVp 
(Schick et al., 2015; Buontempo et al., 2018; Min et al., 2005) and two 
from 6 MV LINACs (Li et al., 2015), including our experiment, we can 
observe considerable differences in the final survival (shown in Fig. 3). 
Low dose rate irradiations lead to higher survival and high dose rate 
irradiations result in lower survival with a more quadratic tendency 
presumably as a result of the lower possibility of cell repair. 
This diversity of results would lead to a significant variation of the 
deduced RBE values, which are obtained from the comparison of the 
neutron data at ILL. At a survival of 1%, depending on the reference dose 
used, thermal neutron RBE values fluctuate from 1.1 to 3.5 (at other 
survivals the variation is even stronger, from 2.1 to 7.4 at Survival of 
50%). For the CBE (Compound biological effectiveness), at 1% survival 
the RBE varies from 3.0 to 5.2. Even if only one data set was considered, 
large uncertainties are found for each calculated RBE (more than 50% in 
some cases), caused by the errors on the fitting of the reference data. 
The observed variability is evidence of the importance of setting a 
reference dose data irradiation type (energy and dose rate). As the main 
objective of reference irradiation used for RBE calculations is to provide 
a good estimation of the biological effect, the more data at the same 
conditions can be found for the reference irradiation, the better. It is also 
important that the irradiation has enough data to provide a good fit in 
order to obtain a final RBE assessment. 
These results indicate the need to improve the medical LINAC A375 
photon irradiations data (or at other photon sources and at different 
dose rates). In combination with the neutron irradiation data at ILL, this 
will allow better estimation of the thermal and boron RBE values asso-
ciated with the BNCT dosimetric estimations. 
Table 1 
Dose components from ILL irradiations of melanoma cells (composition in 
(Maughan et al., 1997)) extracted from MCNPX simulations for the experiment 
in June 2019, with a thermal equivalent neutron flux of 2.85⋅109 cm-2s-1. The 
statistical error from the Monte Carlo simulations is less than 1% and the error 
for the kerma factors used to estimate the dose (Goorley et al., 2002) is less than 







dose rate (Gy/ 
h) 










2.65 0.94 <10-6 0.63  
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4. Conclusion 
A BNCT beam has mixed irradiation fields. The analysis of the in-
dividual dose components and their biological effect is important to 
estimate the total damage. This damage will depend not only on the 
irradiation type, but also on the tissue and end-point. At the cold neutron 
line PF1b at ILL, the response of cell cultures to only thermal neutrons as 
well as to the boron capture reaction can be measured. 
When translating these results to clinical applications, in addition, 
radiobiological data from photon irradiations are required, more pre-
cisely even twice for two distinct steps: first, photons are present at a 
different level as unwanted contamination of any type of neutron beam 
used for BNCT or radiobiological research for BNCT respectively. The 
“pure” neutron effect has to be extracted by subtracting the effect of the 
residual photon contribution. Obviously, with a “purer” neutron beam, 
the photon contribution and hence the uncertainty resulting from this 
deduction is correspondingly reduced and that is the particular strength 
of our new measurements at PF1b. Still, for estimating the RBE of the 
dose components in BNCT, we do require reliable data for photon irra-
diations which represent the reference irradiation and thus the numer-
ator in the RBE calculation. We have found that the dispersion of values 
from previous photon measurements would lead to high uncertainties in 
the derived neutron or boron RBE values. It is therefore necessary to 
perform an accurate estimation of the survival under photon irradiation 
Fig. 2. Clonogenic survival of A375 cells as a function of the dose for the different irradiations performed at the medical LINAC in Granada and at the cold neutron 
source at ILL in Grenoble (data for cells without boron from (Porras et al., 2018)). 
Table 2 
Alpha and beta parameters ( standard error) resulted from fitting, with 
equation (2), the survival results of each irradiation. The data for Dt and DB dose 
components were extracted from the survival data of the ILL irradiations using 
St  SILL=Sγ and SB  SILLBPA=SγSt .  
Radiation αi (Gy-1)  βi(Gy-2)  
LINAC, X-rays (Dγ 0.240.05 0.090.01 
ILL 0.700.21 0.030.08 
ILL, only cold neutrons (Dt)  0.840.05 – 
ILL  BPA 2.020.74 0.000.37 
ILL  BPA, only boron capture (DB)  2.240.25 –  
Fig. 3. Clonogenic survival of A375 cells as a function of the dose for 9 different photon irradiations (Munshi et al., 2005; Munshi et al., 2006; Gomez-Millan et al., 
2012; Schick et al., 2015; Buontempo et al., 2018; Min et al., 2005; Li et al., 2015). Dotted lines for fitting low dose rate data (0.2-0.4 Gy/min), dashed lines for fitting 
medium dose rate data (1–3 Gy/min) and solid lines for fitting high dose rate data (4–6 Gy/min). 
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prior to deriving a reliable value for the neutron or boron RBE. 
An experimental configuration has been described here for the 
reference irradiation of cell cultures using a very precise photon dose 
from a medical LINAC used for conventional photon therapy system - 
which amongst other things is useful in providing a comparison with a 
standard radiation field for which there is a lot of clinical experience. For 
this reason, we plan to perform further irradiations for different cell 
lines at the hospital LINAC in Granada. Ultimately two data sets will be 
required, a low dose rate set (order of Gy/h) for subtracting the effect of 
the residual photon contribution and a high dose rate set (order of Gy/ 
min, representative for clinical radiation therapy) to calculate the RBE 
and CBE values. 
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